FindTrial
Sign In

our study aim to determine whether expression of Fcï?§RIII on peripheral blood mononuclear cells (NK-Tcells& monocytes) and its polymorphism determines the response to treatment to rituximab in pemphigus.

To assess the role of Fcy RIIIA expression in peripheral blood mononuclear cells on treatment response with rituximab in patients of pemphigus- an observational study - NA

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2019/04/018812
Enrollment
100
Registered
2019-04-26
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L100- Pemphigus vulgaris

Interventions

None listed

Sponsors

NIL
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Age 1.More than 18 years. 2. Patients of pemphigus vulgaris or foliaceus who has received rituximab (rheumatoid arthritis protocol i.e. 2 doses each dose of1000mg 2 weeks apart. 3. Received second dose of a cycle of rituximab more than 9 months before inclusion in the study.

Exclusion criteria

Exclusion criteria: 1.Inability to give valid consent. 2.Patients who had active viral infection within 4 weeks before inclusion in the study. 3.Known case of hematologic or solid organ malignancy. 4.Recent vaccinations (within 3 months before inclusion in the study).

Design outcomes

Primary

MeasureTime frame
To determinewhether CD16(Fcï?§RIII)expression in peripheral blood mononuclear cells assessed by flowcytometry correlates with treatment response in patients of pemphigus treated with rituximab following rheumatoid arthritis protocol.Timepoint: 9 months following rituximab—

Secondary

MeasureTime frame
To determine whetherCD16 polymorphism (Fcï?§RIIIA158V) determines the response to treatment to rituximab in patients of pemphigus.Timepoint: Anytime—

Countries

India

Contacts

Public ContactAnkur Sharma

Pgimer Chandigarh

dr_dipankar-de@yahoo.in7087009142

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026